ArticleScientific reports2019
Delivery of Rapamycin Using In Situ Forming Implants Promotes Immunoregulation and Vascularized Composite Allograft Survival.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Challenges and opportunities in vascularized composite allotransplantation of joints: a systematic literature review.Frontiers in immunology · 2023Pooled it
- Systematic review of emerging technologies in vascularized composite allotransplantation.Frontiers in transplantation · 2026Review
- A local drug delivery system prolongs graft survival by dampening T cell infiltration and neutrophil extracellular trap formation in vascularized composite allografts.Frontiers in immunology · 2024Article
- Transcriptome profiling of immune rejection mechanisms in a porcine vascularized composite allotransplantation model.Frontiers in immunology · 2024Article
- Cellular activation pathways and interaction networks in vascularized composite allotransplantation.Frontiers in immunology · 2023Review
- Implantable Immunosuppressant Delivery to Prevent Rejection in Transplantation.International journal of molecular sciences · 2022Review
- Local FK506 implants in non-human primates to prevent early acute rejection in vascularized composite allografts.Annals of translational medicine · 2021Article
- Rapamycin Eyedrops Increased CD4International journal of molecular sciences · 2020Article
- The cellular basis of organ failure in sepsis-signaling during damage and repair processes.Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2020Review
- Emerging strategies for tissue engineering in vascularized composite allotransplantation: A review.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascularized composite allotransplantation (VCA), such as hand and face transplantation, is emerging as a potential solution in patients that suffered severe injuries. However, adverse effects of chronic high-dose immunosuppression regimens strongly limit the access to these procedures. In this study, we developed an in situ forming implant (ISFI) loaded with rapamycin to promote VCA acceptance. We hypothesized that the sustained delivery of low-dose rapamycin in proximity to the graft may promote graft survival and induce an immunoregulatory microenvironment, boosting the expansion of T regulatory cells (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.